y-Hydroxybutyrate (GHB) remains a popular drug of abuse, commonly known as liquid ecstasy;it is often ingested with alcohol, with other drugs of abuse, or as its precursors y-butyrolactone and 1, 4-butanediol. GHB intoxication results in CNS and respiratory depression and overdoses result in coma and death. A recent review stated that GHB was the second most common drug detected in urine of young people presenting with drug-induced coma, just behind cocaine. There is currently no specific treatment for GHB overdoses. The goal of this proposal is to identify specific therapeutic interventions for the treatment of GHB overdoses, when GHB is ingested alone or with ethanol. We have reported that GHB undergoes concentration-dependent reabsorption in the kidney, due to transport by monocarboxylate transporters (MCTs), and that the administration of MCT inhibitors can increase the renal and total clearances of GHB. Results from our Preliminary Studies indicate that low doses of L-lactate combined with mannitol (an osmotic diuretic) increase GHB renal and total clearances, decrease serum concentrations, and decrease the return to righting reflex (RRR), a pharmacological end-point in rats, following high doses of GHB: the combined treatment resulted in an additive/synergistic effect on RRR. Our hypothesis is that administration of MCT inhibitors alone, or combined with mannitol, represents potential strategies for treating patients following overdoses of GHB.
Our specific aims are: (1) To determine the mechanism(s) underlying the effect of MCT inhibitors on GHB toxicokinetics (TK) and toxicodynamics (TD). We will test the hypothesis that MCT inhibitors alter the TK and TD of GHB by multiple mechanisms: increased renal clearance of GHB resulting in an increased total clearance;inhibition of GHB brain uptake;and decreased formation of GABA in the brain. 2) To determine the effects of mannitol on GHB TK and TD, and the mechanism(s) underlying the enhanced pharmacological effect of L-lactate produced by concomitant mannitol administration. (3) To determine the mechanisms for the effect of ethanol on the TK/TD of GHB, and the efficacy of MCT inhibitors and mannitol on GHB TK and TD following the concomitant administration of ethanol. (4) To perform a clinical study in normal volunteers to evaluate the efficacy of L-lactate/mannitol treatment in increasing the elimination and decreasing plasma concentrations of GHB. Methods used in the proposal include in vivo studies in rats to determine plasma, brain tissue and extracellular fluid (ECF) concentrations (by microdialysis) of GHB and the neurotransmitter y-aminobutyric acid (GABA). The concentration-effect (RRR) relationship for GHB will be determined. Effects on brain uptake will be determined using in situ brain perfusion, and in vitro studies of GHB brain metabolism will utilize mitochondrial and cytosolic tissue preparations. The clinical study will provide "proof-of-concept" that the administration of L-lactate and mannitol can increase the elimination of GHB in humans, thereby representing a potential treatment for GHB overdoses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA023223-04
Application #
8017432
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Frankenheim, Jerry
Project Start
2008-04-01
Project End
2012-04-30
Budget Start
2011-02-01
Budget End
2012-04-30
Support Year
4
Fiscal Year
2011
Total Cost
$297,877
Indirect Cost
Name
State University of New York at Buffalo
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Dave, Rutwij A; Morris, Marilyn E (2016) A quantitative threshold for high/low extent of urinary excretion of compounds in humans. Biopharm Drug Dispos 37:287-309
Dave, Rutwij A; Morris, Marilyn E (2016) Novel high/low solubility classification methods for new molecular entities. Int J Pharm 511:111-26
Dave, Rutwij A; Morris, Marilyn E (2015) Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in rats. J Pharmacokinet Pharmacodyn 42:497-513
Dave, Rutwij A; Morris, Marilyn E (2015) Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humans. Drug Metab Dispos 43:73-81
Vijay, Nisha; Morse, Bridget L; Morris, Marilyn E (2015) A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose. Pharm Res 32:1894-906
An, Guohua; Wang, Xiaodong; Morris, Marilyn E (2014) Flavonoids are inhibitors of human organic anion transporter 1 (OAT1)-mediated transport. Drug Metab Dispos 42:1357-66
Vijay, Nisha; Morris, Marilyn E (2014) Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des 20:1487-98
Morris, Marilyn E; Dave, Rutwij A (2014) Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS J 16:705-13
Morse, Bridget L; Vijay, Nisha; Morris, Marilyn E (2014) Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate. AAPS J 16:756-70
Vijay, Nisha; Morris, Marilyn E (2014) Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid. J Pharm Sci 103:3310-5

Showing the most recent 10 out of 25 publications